Nordea Investment Management
CTMX icon

Nordea Investment Management’s CytomX Therapeutics CTMX Stock Holding History

Nordea Investment Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-93,613
Closed -$1.45M – 1030
2017
Q2 		$1.45M Buy
+93,613
New +$1.41M ﹤0.01% 749

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nordea Investment Management's CTMX Position: Q3 2017 in Review

Nordea Investment Management sold out of CytomX Therapeutics (CTMX) in Q3 2017, closing a stake of 93,613 shares — an estimated $1.45M sold.

Nordea Investment Management first reported a position in CTMX in Q2 2017 and held it in 1 quarter. The position peaked at $1.45M in Q2 2017. 97 funds tracked by Wall St. Rank hold CTMX as of Q3 2017.

  • Nordea Investment Management reported no remaining CytomX Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Nordea Investment Management sold 93,613 CytomX Therapeutics shares in Q3 2017, an estimated $1.45M.
  • Nordea Investment Management first reported a position in CytomX Therapeutics in Q2 2017 and held it in 1 quarter.
  • Nordea Investment Management's CytomX Therapeutics position peaked at $1.45M in Q2 2017.
  • 97 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2017.

Based on Nordea Investment Management's 13F filing for Q3 2017, filed 9 Nov 2017.